50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to become a leader in high-barrier to entry generic pharmaceuticals.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-05-0489% match
“Our mission is to be a global leader in generics, innovative medicines and biopharmaceuticals, improving the lives of patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-1277% match
“Our mission is to become a leading fully-integrated pharmaceutical company delivering new medicines to patients with unmet medical needs.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-03-2871% match
“Our mission is to build a world-class biopharmaceutical and biotechnology company, with a leading position in key therapeutic areas.”In use 2020 – now·1 sighting·SEC Form 20-F, filed 2020-03-1270% match
“Our mission is to provide access to high-quality, innovative, impactful, and affordable medicines to billions more people globally.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-02-2570% match
“Our mission is to become a leading global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-01-2469% match
“Our mission is to develop and commercialize first-in-class medicines based on novel targets to improve patients’ lives.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-03-2469% match
“Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0769% match
“The Company's mission is to identify, develop and commercialize specialty pharmaceutical products that exceed the expectations of patients, customers and stockholders with a high-performance culture and preeminent ethical standards.”In use 2018 – now·1 sighting·SEC Form 10-K, filed 2018-03-0869% match
“Our mission is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0469% match
“Our mission is to develop, register and commercialize safe and effective drugs, with novel mechanisms of action, to meet the major unmet medical needs of patients on a global basis.”In use 2012 – now·1 sighting·SEC Form 10-K, filed 2012-03-1569% match
“Our mission is to be leaders in Israel’s biopharmaceutical industry, to identify promising drug compounds and creatively drive the development process towards commercialization.”In use 2020 – now·1 sighting·SEC Form 20-F, filed 2020-03-1269% match
“Our mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2669% match
“Our mission is to become a leader in bringing innovative cancer treatments to the market and to improve patient health outcomes.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2068% match
“Our mission is to be a leading global biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that improve the lives of patients.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2668% match
“Our mission is to be a leader in developing and manufacturing pharmaceutical products in unique and convenient oral delivery formats using science and innovation to improve people's lives.”In use 2009 – now·1 sighting·SEC Form 10-K, filed 2009-04-2468% match
“Our mission is to build an ophthalmology-focused biopharmaceutical company that capitalizes on the gaps that we believe increasingly exist in the ophthalmology sector between single product companies and large, multi-product pharmaceutical companies.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-0668% match
“Our mission is to build a major ophthalmic pharmaceutical company.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-02-2768% match
“Our mission is to build a community and company capable of sustainably discovering, developing and delivering to patients innovative, important new medicines that will make a material difference in their health, well-being and lives.”In use 2009 – now·1 sighting·SEC Form 10-K, filed 2009-03-1367% match
“Our mission is to identify, acquire, and accelerate the development and commercialization of medicines that we believe have the potential to offer clinically meaningful, differentiated benefits to patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2867% match
“Our mission is to become the world leader in the sustainable manufacture of KLH and use our unique, proprietary methods and intellectual property to serve the growing demand for KLH in immunotherapeutic and immunodiagnostic markets.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-12-1467% match
“Our mission is to discover and develop best- and first-in-class medicines for a broad range of difficult-to-treat diseases in collaboration with our partners.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-04-0867% match
“Our mission is to profitably accelerate drug discovery.”In use 2005 – now·1 sighting·SEC Form 10-K/A, filed 2005-04-2967% match
“Our mission is to transform the lives of patients through the creation of novel gene control medicines by building a fully integrated, leading biopharmaceutical company.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-03-2067% match
“Our mission is to be the leader in highly complex products and demanding regulatory environments.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-11-1467% match
“Our mission is to solve unmet medical needs by commercializing discoveries from research universities and medical centers We are a biopharmaceutical company that seeks to bridge the “bench-to-bedside” gap between medical research discoveries and patient solutions.”In use 2022 – now·1 sighting·SEC Form S-1/A, filed 2022-04-1167% match
“Our mission is to discover, develop and ultimately deliver medicines that are transformational for patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2867% match
“Our mission is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2567% match
“Our mission is to develop therapeutic products with the potential to address high unmet medical needs by identifying promising clinical-stage candidates and advancing their development to create products that will improve patients’ lives.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2167% match
“Our mission is to become the leading global pharmaceutical company focused on women’s health and endocrine diseases.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-06-1467% match
“Our mission is to become a global leader in the treatment of rare diseases through commercializing, developing and acquiring novel rare disease products.”In use 2021 – now·1 sighting·SEC Form 424B4, filed 2021-01-1467% match
“Our mission is to discover and develop effective biologic treatments for people with life-threatening conditions and to evolve Inhibrx into a commercial-stage biopharmaceutical company with a differentiated and sustainable product portfolio by focusing on the following:.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2866% match
“Our mission is to become a global leader in developing better and safer radioimmunotherapy and antibody-based oncology therapies addressing clear unmet medical needs and, as such, have a transformational impact on the lives of patients.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-0466% match
“Our mission is to be a leading provider of superior molecular solutions.”In use 2008 – now·1 sighting·SEC Form 10-K, filed 2008-03-0766% match
“Our mission is to expand our portfolio into a wide range of muscle diseases and become a leader in this area by advancing life-transforming therapeutics for patients with serious muscle diseases.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-0466% match
“Our mission is to enable anyone and any company to use our integrated open-access drug discovery and development platform to discover and develop new therapeutic products to benefit patients worldwide.”In use 2015 – now·1 sighting·SEC Form 20-F, filed 2015-04-1566% match
“Our mission is to discover or acquire novel therapeutic product candidates targeting unmet medical needs in attractive specialty markets.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-03-1566% match
“Compugen’s mission is to be the world leader in the discovery and licensing of product candidates to the therapeutic and diagnostic industries under milestone and revenue sharing agreements.”In use 2010 – now·1 sighting·SEC Form 20-F, filed 2010-03-1166% match
“Our mission is to improve the lives of patients throughout the world by successfully identifying, developing and commercializing innovative specialty biopharmaceutical products.”In use 2014 – now·1 sighting·SEC Form 10-K, filed 2014-02-2866% match
“Our mission is to build a leading, fully integrated global rare disease company using our patient-centric approach to identify and develop life-transforming medicines for the treatment of severe rare diseases.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-04-1966% match
“Our mission is to keep pharmaceuticals secure from the manufacturer/distributor to the patient by delivering integrated solutions across the United States and Canada.”In use 2024 – now·1 sighting·SEC Form S-1/A, filed 2024-05-3166% match
“Our mission is to accelerate scientific and medical breakthroughs and deliver well-tolerated medicines with greater efficacy and safety to people with the deadliest cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0566% match
“Our mission is to improve health for all with great, innovative, affordable medicines so that people with life-changing or chronic conditions can gain access to the medicines they need, physicians can treat patients without barriers to prescribing, and health systems can afford to make those medicines available, without restrictions, to the populations they serve in a financially sustainable manner.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-2366% match
“Our mission is to build the world’s leading endocrine company that pioneers new therapeutics to help patients better control their disease and improve their daily lives.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2666% match
“Our mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest unmet medical need – aggressive cancers where current therapies are inadequate.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-02-2966% match
“Our mission is to become a leader in this category and we see the future as a growing market segment which fits our mission.”In use 2014 – now·1 sighting·SEC Form 10-K, filed 2014-09-1566% match
“Our mission is to provide drug and product developers with superior scientific research, high-quality research models and innovative analytical instrumentation in order to bring revolutionary new drugs and products to market quickly and safely.”In use 2021 – now·1 sighting·SEC Form S-1, filed 2021-12-2366% match
“Our mission is to become the leading company in precision genetic medicines by discovering, developing, manufacturing, and ultimately commercializing a new class of medicines through our proprietary base editing technology, with the goal of providing life-long cures to patients suffering from serious diseases.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-10-0166% match
“Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-02-2366% match
“Our mission is to transform the lives of patients with chronic IMIDs through the development of oral, safe and effective small molecule product candidates.”In use 2026 – now·1 sighting·SEC Form S-1/A, filed 2026-01-2765% match
Showing 1–50 of 50